Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy

Company Initiates Preclinical Development of Cells Capable of Seeking and Destroying Cancer

May 19, 2016, 07:00 ET from Regen BioPharma Inc.

SAN DIEGO, May 19, 2016 /PRNewswire/ --

Regen BioPharma, Inc. (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a preclinical development program aimed at creating the first cord blood based cancer immunotherapeutic product leveraging its NR2F6 immunological checkpoint.  In a provisional patent application, Regen described a generation of cord blood derived killer cells whose anti-cancer activity was potentiated by gene silencing.  The product in development will be a "universal donor" cellular immunotherapy, which can be shipped frozen to the site of use and does not involve complex cellular manipulations by the treating institution.

"Developing a universal donor immunotherapy will substantially reduce costs of clinical implementation and allow for wide access to treatment including at institutions that do not possess cellular processing abilities.  To our knowledge, "universal donor" cellular immunotherapies have not been developed to date.  We believe ucVax will possess both therapeutic and commercial advantages as compared to other immunotherapies," said David Koos, Ph.D., Chairman and CEO of Regen BioPharma.

Currently cancer cellular immunotherapies involve extraction of patient blood cells, manipulation of the cells outside of the body, followed by subsequent re-infusion.  The disadvantage of these approaches include the costs of generating personalized cellular products, as well as the need for each institution to possess cell manipulation facilities.  

"We are pleased to announce expansion of our NR2F6 gene-silencing technologies to the area of universal donor cellular products.  ucVax leverages experimental data gathered from our ongoing work in the development of dCellVax (IND # 16200) and tCellVax (IND #16928), both of which are personalized cellular immunotherapies," said Harry Lander Ph.D., President and Chief Scientific Officer of Regen BioPharma. "By using cord blood cells as the starting population for generation of ucVax, we overcome the problem of immune rejection by the patient receiving the therapy, thus potentially allowing the therapy to be used by everyone in need."

About Regen BioPharma, Inc. 

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

http://www.regenbiopharma.com and http://www.regenbiopharmainc.com  

Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm


Contact:

Regen BioPharma Inc.    
David R. Koos, PhD    
Chairman & Chief    
+1-619-702-1404 Phone   
+1-619-330-2328 Fax
David.koos@regenbiopharma.com

The Dorsee Company
Debra Dorsee
Executive Office
+1-(858)-229-6082
Debbie@thedorseecompany.com

SOURCE Regen BioPharma Inc.